Evidence map›Paper›PMID 27370326›Full record

ArticleBMC veterinary research2016

Mucopolysaccharidosis VI in cats - clarification regarding genetic testing.

Leslie A Lyons, Robert A Grahn, Francesca Genova, Michela Beccaglia, John J Hopwood, Maria Longeri

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Leslie A LyonsDepartment of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri - Columbia, Columbia, MO, 65211, USA. lyonsla@missouri.edu.
Robert A GrahnVeterinary Genetics Laboratory, School of Veterinary Medicine, University of California - Davis, Davis, CA, USA.
Francesca GenovaDepartment of Veterinary Medicine, University of Milan, Milan, Italy.
Michela BeccagliaAmbulatorio Veterinario, Lissone, Monza e Brianza, Italy.
John J HopwoodLysosomal Diseases Research Unit, South Australian Health and Medical Research Institute, Adelaide, Australia.
Maria LongeriDepartment of Veterinary Medicine, University of Milan, Milan, Italy.
University of Milan · ITFondazione Lanza · ITMissouri College · USSouth Australian Health and Medical Research Institute · AUUniversity of California, Davis · US

Funding

Genetic Mapping Resources for Common Mammalian DiseasesR24RR016094 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI LYONS, LESLIE A · 2002 to 2011
$3.0M
Genetic Mapping Resources for Common Mammalian DiseasesR24OD010928 · OD · UNIVERSITY OF MISSOURI-COLUMBIA · PI LYONS, LESLIE A · 2012 to 2015
$911k
NCRR NIH HHS R24 RR016094NIH HHS R24 OD010928
6 · The paper itself

Abstract

The release of new DNA-based diagnostic tools has increased tremendously in companion animals. Over 70 different DNA variants are now known for the cat, including DNA variants in disease-associated genes and genes causing aesthetically interesting traits. The impact genetic tests have on animal breeding and health management is significant because of the ability to control the breeding of domestic cats, especially breed cats. If used properly, genetic testing can prevent the production of diseased animals, causing the reduction of the frequency of the causal variant in the population, and, potentially, the eventual eradication of the disease. However, testing of some identified DNA variants may be unwarranted and cause undo strife within the cat breeding community and unnecessary reduction of gene pools and availability of breeding animals. Testing for mucopolysaccharidosis Type VI (MPS VI) in cats, specifically the genetic testing of the L476P (c.1427T>C) and the D520N (c.1558G>A) variants in arylsulfatase B (ARSB), has come under scrutiny. No health problems are associated with the D520N (c.1558G>A) variant, however, breeders that obtain positive results for this variant are speculating as to possible correlation with health concerns. Birman cats already have a markedly reduced gene pool and have a high frequency of the MPS VI D520N variant. Further reduction of the gene pool by eliminating cats that are heterozygous or homozygous for only the MPS VI D520N variant could lead to more inbreeding depression effects on the breed population. Herein is debated the genetic testing of the MPS VI D520N variant in cats. Surveys from different laboratories suggest the L476P (c.1427T>C) disease-associated variant should be monitored in the cat breed populations, particularly breeds with Siamese derivations and outcrosses. However, the D520N has no evidence of association with disease in cats and testing is not recommended in the absence of L476P genotyping. Selection against the D520N is not warranted in cat populations. More rigorous guidelines may be required to support the genetic testing of DNA variants in all animal species.

Indexed as

Genetic VariationAnimalsBreedingCat DiseasesCatsGenetic TestingGenotypeMucopolysaccharidosis VIARSBDNAFelineFelis silvestris catusGenetic testingMPS VIN-acetylgalactosamine-4-sulfatase

Identifiers

PMID27370326
PMCPMC4930586
OpenAlexW2474155452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.